SCHEMBL2260059

SCHEMBL2260059

CN(CCOc1ccc(C=C2NC(=O)SC2=O)cc1)c1ccccn1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.68
ALDH1A1 P00352 2/20 0.68
MAPT P10636 2/20 0.68
PKM P14618 2/20 0.68
HTT P42858 1/20 0.68
PPARG P37231 10/20 0.62
L3MBTL1 Q9Y468 1/20 0.61
RARG P13631 1/20 0.54
RXRA P19793 1/20 0.54
KMT2A Q03164 1/20 0.51
HPGD P15428 3/20 0.50
CSNK2A2 P19784 1/20 0.50
CLK1 P49759 1/20 0.50
CSNK2B P67870 1/20 0.50
CSNK2A1 P68400 1/20 0.50
DYRK1A Q13627 1/20 0.50
DYRK2 Q92630 1/20 0.50
DYRK1B Q9Y463 1/20 0.50
PIM1 P11309 1/20 0.44
PIM2 Q9P1W9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850986 0.89 PPARG (0.57) KDM4EALDH1A1MAPTPKMHTT
SCHEMBL1847035 0.88 PPARG (0.78) KDM4EALDH1A1MAPTPKMHTT
SCHEMBL5111753 0.88 PPARG (0.78) KDM4EALDH1A1MAPTPKMHTT
SCHEMBL2260054 0.88 PPARG (0.78) KDM4EALDH1A1MAPTPKMHTT
SCHEMBL8117117 0.86 PPARG (0.58) KDM4EALDH1A1MAPTPKMHTT
SCHEMBL28578160 0.85 ALDH1A1 (0.52) KDM4EALDH1A1MAPTPKMHTT
SCHEMBL9327176 0.85 PPARG (0.64) KDM4EALDH1A1MAPTPKMHTT
SCHEMBL2774800 0.83 PPARG (0.73) KDM4EALDH1A1MAPTPKMHTT
SCHEMBL1848912 0.81 PPARG (0.79) KDM4EALDH1A1MAPTPKMHTT
Trifluoroacetic Acid SCHEMBL6608295 0.81 PPARG (0.67) KDM4EALDH1A1MAPTPKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010013141-A2 SUBSTANTIALLY PURE ROSIGLITAZONE HYDROGEN SULFATE ACTAVIS GROUP PTC EHF (IS) 2010-02-04 WO claimed
US-20090234128-A1 Process for the Preparation of Intermediates of Rosiglitazone, Rosiglitazone and New Polymorphic Forms Thereof LOPEZ ERNESTO DURAN 2009-09-17 US claimed
EP-2029585-A2 PROCESS FOR PREPARATION OF INTERMEDIATES OF ROSIGLITAZONE, ROSIGLITAZONE AND POLYMORPHIC FORMS THEREOF Medichem, S.A. (ES) 2009-03-04 EP claimed
US-7351832-B2 Process for the preparation of thiazolidinedione derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2008-04-01 US claimed
WO-2008010089-A2 PROCESS FOR PREPARATION OF INTERMEDIATES OF ROSIGLITAZONE, ROSIGLITAZONE AND POLYMORPHIC FORMS THEREOF MEDICHEM, S.A. (US) 2008-01-24 WO claimed
EP-1770092-A1 Process for the preparation of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione SMITHKLINE BEECHAM PLC (GB) 2007-04-04 EP claimed
US-20070066662-A1 PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES SMITHKLINE BEECHAM PLC 2007-03-22 US claimed
US-7091359-B2 Process for the preparation of thiazolidinedione derivatives SMITHKLINE BEECHAM PLC (GB) 2006-08-15 US claimed
US-20060106221-A1 Process for the preparation of thiazolidinedione derivatives SMITHKLINE BEECHAM PLC 2006-05-18 US claimed
US-6632947-B2 By selective reduction of the exocyclic double bond in a benzylidene thiazolidine-2,4-dione moiety by complex hydride reducing agents such as lithium tri-sec-butyl borohydride SMITHKLINE BEECHAM PLC (GB) 2003-10-14 US claimed
US-20020042519-A1 Process for the preparation of substituted thiazolidinedione SMITHKLINE BEECHAM P.L.C. 2002-04-11 US claimed
EP-1028960-A1 PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES SmithKline Beecham p.l.c. (GB) 2000-08-23 EP claimed
EP-0970063-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED THIAZOLIDINEDIONE SMITHKLINE BEECHAM PLC (GB) 2000-01-12 EP claimed
EP-0615549-B1 PROCESS FOR THE PREPARATION OF PHARMACEUTICALLY ACTIVE THIAZOLIDINE OR OXAZOLIDINE COMPOUNDS BY A YEAST REDUCTASE SMITHKLINE BEECHAM PLC (GB) 1999-06-09 EP claimed
WO-1999023095-A1 PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 1999-05-14 WO claimed
WO-1998037073-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED THIAZOLIDINEDIONE SMITHKLINE BEECHAM PLC (GB) 1998-08-27 WO claimed
EP-0842925-A1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1998-05-20 EP claimed
US-5232925-A Treating hypertension BEECHAM GROUP P.L.C. (GB) 1993-08-03 US claimed
US-5002953-A Substituted Thiazolidinedione Derivatives BEECHAM GROUP P.L.C. (GB) 1991-03-26 US claimed
EP-0306228-A1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1989-03-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234128-A1 Process for the Preparation of Intermediates of Rosiglitazone, Rosiglitazone and New Polymorphic Forms Thereof CYP11B1, PPARD, SLC5A1 KDM4E 2871/4885ALDH1A1 480/4885MAPT 4803/4885
US-20070066662-A1 PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES ARSA, TALDO1, NAT1 KDM4E 4296/4885ALDH1A1 150/4885MAPT 272/4885
US-20020042519-A1 Process for the preparation of substituted thiazolidinedione TALDO1, CYP11B1, CYP11B2 KDM4E 3071/4885ALDH1A1 180/4885MAPT 57/4885
US-20060106221-A1 Process for the preparation of thiazolidinedione derivatives ARSA, TALDO1, NAT1 KDM4E 4296/4885ALDH1A1 150/4885MAPT 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.